Letter--Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN Evidence Blocks.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29083976.
- Also identified by DOI 10.18553/jmcp.2017.23.11.1202 and PMC identifier 10397700.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This research was funded by Astellas Pharma and Medivation, which was acquired by Pfizer in 2016. Astellas Pharma and Medivation are the co-developers of enzalutamide. Flanders, Brown, Massoudi, and Schultz are employees of Astellas Pharma. Ramaswamy is an employee of Pfizer and holds stock in Johnson & Johnson. Flanders holds stock in Johnson & Johnson, AbbVie, and Abbott Labs.
Medical subject headings
- Evidence-Based Medicine
- Phenylthiohydantoin
- Practice Guidelines as Topic
- Prostatic Neoplasms, Castration-Resistant